IP Verse

Rna Containing Composition For Treatment Of Tumor Diseases

PatentPatent Analysis

EP3173092

CUREVAC
Application Number
EP16166757A
Filing Date
Apr 22, 2016
Status
Revoked
Jul 5, 2024
Grant Date
Jun 26, 2019
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3283059B1
EP4155409B1
EP4108769B1

Bibliography

The patent EP3173092B1 was granted to Curevac on Jun 26, 2019 following the initial filing on Apr 22, 2016 under the application number EP16166757A . The current legal status of the patent is Revoked.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions filed by Competitors

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

BIONTECH RNA PHARMACEUTICALSMar 26, 2020ADMISSIBLE
ETHERNA IMMUNOTHERAPIESMar 26, 2020ADMISSIBLE
KONIG SZYNKA TILMANN VON RENESSEMar 26, 2020ADMISSIBLE
FRIEDRICHMar 26, 2020WITHDRAWN
SANOFIMar 26, 2020WITHDRAWN

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents